VPC
Vestal Point Capital Portfolio holdings
AUM
$2.73B
1-Year Est. Return
128.57%
This Fund
S&P 500
1 Year Est. Return
+128.57%
AUM
$2.73B
AUM Growth
+$522M
(+24%)
Holding
105
Top Buys
| 1 | +$134M | |
| 2 | +$118M | |
| 3 | +$104M | |
| 4 |
ABVX
Abivax
ABVX
|
+$98.2M |
| 5 |
Merck
MRK
|
+$72.7M |
Top Sells
| 1 | +$104M | |
| 2 | +$87.8M | |
| 3 | +$76.8M | |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$70.3M |
| 5 |
Becton Dickinson
BDX
|
+$60.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABVX
1
Abivax
ABVX
$9.13B
| $256M | 9.4% |
1,900,000
+900,000
|
|
||
2
Arcellx
ACLX
$6.69B
| $191M | 7% |
2,925,000
+1,675,000
|
|
||
3
Terns Pharmaceuticals
TERN
$5.06B
| $182M | 6.67% |
+4,500,000
|
|
||
4
BioMarin Pharmaceuticals
BMRN
$11.3B
| $178M | 6.54% |
3,000,000
+2,170,000
|
|
||
5
Globus Medical
GMED
$11.5B
| $111M | 4.08% |
1,275,000
+25,000
|
|
||
6
Nurix Therapeutics
NRIX
$1.55B
| $89M | 3.26% |
4,690,000
+1,215,000
|
|
||
7
Alcon
ALC
$37.7B
| $87.1M | 3.19% |
1,105,000
+5,000
|
|
||
8
DexCom
DXCM
$24.7B
| $84.6M | 3.1% |
1,275,000
+625,000
|
|
||
|
9
Merck
MRK
$286B
| $81.6M | 2.99% |
+775,000
|
|
||
10
Taysha Gene Therapies
TSHA
$1.23B
| $75.6M | 2.77% |
13,750,000
+8,250,000
|
|
||
11
Abbott
ABT
$188B
| $75.2M | 2.76% |
600,000
+350,000
|
|
||
12
Immatics
IMTX
$1.24B
| $64.3M | 2.36% |
6,125,000
-225,000
|
|
||
13
Tyra Biosciences
TYRA
$1.95B
| $63.8M | 2.34% |
2,425,000
|
|
||
|
BCAX
14
Bicara Therapeutics
BCAX
$1.24B
| $60.2M | 2.21% |
3,575,000
-1,525,000
|
|
||
15
Arrowhead Research
ARWR
$7.71B
| $59.8M | 2.19% |
+900,000
|
|
||
16
Enliven Therapeutics
ELVN
$1.66B
| $59M | 2.16% |
3,830,000
+2,670,000
|
|
||
17
Disc Medicine
IRON
$2.29B
| $58.4M | 2.14% |
735,000
+235,000
|
|
||
18
Jazz Pharmaceuticals
JAZZ
$11B
| $49.3M | 1.81% |
290,000
-210,000
|
|
||
19
Day One Biopharmaceuticals
DAWN
$2.2B
| $48.5M | 1.78% |
5,200,000
+2,525,000
|
|
||
20
Lexeo Therapeutics
LXEO
$486M
| $44.4M | 1.63% |
4,475,000
+1,225,000
|
|
||
21
Alto Neuroscience
ANRO
$692M
| $44.2M | 1.62% |
2,485,000
+1,535,000
|
|
||
22
Apogee Therapeutics
APGE
$4.95B
| $41.5M | 1.52% |
550,000
+125,000
|
|
||
23
Olema Pharmaceuticals
OLMA
$1.18B
| $41.3M | 1.51% |
+1,650,000
|
|
||
24
Axsome Therapeutics
AXSM
$7.98B
| $38.4M | 1.41% |
210,000
+60,000
|
|
||
25
Ascendis Pharma
ASND
$13.9B
| $37.3M | 1.37% |
175,000
-425,000
|
|